A post market registry of abluminus® sirolimus eluting coronary stent system for percutaneous intervention in patients with diabetes mellitus.

  • Principal Investigator
    Dr. Luca Testa
  • 5,000

• The purpose of this registry is to capture clinical data of ABLUMINUS sirolimus eluting stent in real world, all comer patients with Diabetes Mellitus.
• Prospective, Observational, Multi‐center/worldwide clinical registry targeting 5000 patients. All the patients will be followed up for up to 5 years.

Primary Endpoints:

Target Lesion Failure that is composite of cardiac death, target-vessel myocardial infarction, and clinically indicated target lesion revascularisation within 12 months.

N = No. of sites